M2 PHARMA-December 6, 2017-Global Gastroparesis
Drugs Market Expected to Reach USD 6,486m by 2022, Allied Market Research Forecasts
Background: Whether Helicobacter pylori infection is associated with diabetic gastroparesis
(DGP) is unclear.
a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, recently announced positive topline results from the Company's comparative exposure pharmacokinetic (PK) study for Gimoti, the Company's patented nasal delivery formulation of metoclopramide for the relief of symptoms associated with acute and recurrent diabetic gastroparesis
means paralyzed stomach and may cause side effects such as malnutrition, nausea and vomiting, according to the (https://www.
I was diagnosed with gastroparesis
, paralysis of the stomach muscles which meant food passing through much more slowly.
is a chronic disease of stomach mobility, defined as delay in the emptying of food from the stomach without mechanical obstruction.
So we conclude that ranitidine is a better choice for patients suffering from gastroesophageal reflux disease (GERD) along with gastroparesis
as it enhances the prokinetic effect of metoclopramide.
It is an oral investigational drug in development for the treatment of gastroparesis
, and is presently being examined in a large, multinational Phase 2b study in patients with confirmed gastroparesis
of either diabetic or idiopathic origin.
com)-- According to the latest market report published by Persistence Market Research titled "Diabetic Gastroparesis
Treatment Market: Global Industry Analysis and Forecast, 2016 - 2024," revenue from the global diabetic gastroparesis
treatment market is projected to register a CAGR of 4.
GlobalData's clinical trial report, "Diabetic Gastroparesis
Global Clinical Trials Review, H1, 2016" provides an overview of Diabetic Gastroparesis
clinical trials scenario.
USPRwire, Mon Oct 19 2015] Global Markets Direct's, 'Diabetic Gastroparesis
- Pipeline Review, H2 2015', provides an overview of the Diabetic Gastroparesis
's therapeutic pipeline.
75 mcg/kg/day) in the presence of achlorhydria and decreased gastric motility associated with gastroparesis
excluding other factors that could potentially result in malabsorption.